NCT05156788进行中（未招募）2 期
A Single-arm, Multi-center, Phase II Study of Tislelizumab, Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
Shanghai Zhongshan Hospital2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年12月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- R0 resection rate
研究概览
简要总结
The aim of this study is to assess the R0 resection rate of tislelizumab combined with Lenvatinib and Gemox chemotherapy in the conversion therapy of potentially resectable locally advanced BTC.
详细描述
Translational therapy refers to methods such as chemotherapy, radiotherapy, immunotherapy, targeted and combined therapy to shrink tumors, reduce tumor biological behavior, and achieve secondary resection. The success rate of transformation depends on the objective response rate of the treatment method (Objective response rate, ORR). The latest review showed that 132 patients with unresectable ICC had undergone chemotherapy, chemoembolization, radiotherapy embolization or combination therapy, and 27 patients received downgrade resection. The research of our group using PD-1 antibody combined with lenvatinib and Gemox chemotherapy in the first-line treatment of unresectable advanced cholangiocarcinoma (NCT03951597, 2020ESMO, 2021ASCO) showed that the ORR was 80% and the disease control rate (DCR) It reached 93.3% (28/30), of which 3 cases underwent successful radical resection after downstage. These data suggest that PD1 monoclonal antibody combined with lenvatinib and Gemox chemotherapy may be an ideal conversion therapy for patients with potentially resectable advanced biliary system tumors, but there is currently no evidence-based basis.
This study explores the efficacy and safety of PD1 monoclonal antibody combined with Lenvatinib and Gemox chemotherapy in potentially resectable advanced BTC conversion therapy. It has certain clinical significance in order to increase the R0 surgical resection rate of BTC patients and improve patient survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged 18-70
- •The patient must sign an informed consent form before joining the group, understand and be willing to sign a written informed consent form
- •Potentially resectable locally advanced BTC (including ICC, PBDT and GBC) confirmed by histology or cytology, agree to provide previously stored tumor tissue specimens or fresh biopsy tumor lesions for biomarker detection
- •Local progress, failure to achieve R0 resection, and no distant metastasis, with potential resection
- •At least one measurable lesion (RECIST 1.1)
- •Have never received systemic treatment for biliary tumors in the past
- •Eastern Cooperative Oncology Group (ECOG) performance status score ECOG PS 0-1
- •Liver function classification is Child-Pugh A
- •The bone marrow, liver and kidneys are fully functional and reach the following clinical laboratory evaluation standards within 7 days before treatment:
- •Blood indicators:
- •Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet ≥ 90 × 109/L, hemoglobin ≥ 90 g/L.
- •Liver function indicators:
- •AST and ALT are both ≤3×ULN (upper limit of normal value); total bilirubin ≤1.5×ULN
- •Kidney function indicators:
- •Serum creatinine≤1.5×ULN
- •Coagulation index:
- •International normalized ratio (INR) ≤ 1.2 or prothrombin time (PT) ≤ 1.2×ULN
- •Obstructive jaundice, after PTCD or ERCP treatment, if the liver function indicators meet the requirements for entry, it can be considered for entry:
- •If the subject has HBV or HCV infection, the following conditions must be met:
- •For inactive/asymptomatic carriers of HBV, chronic, or active HBV:
- •HBV deoxyribonucleic acid (DNA) <2000 copies/mL during the screening period. Remarks: Patients with HBV DNA>2000 copies/mL should be treated according to treatment guidelines. Patients who received antiviral drug treatment at the time of screening should have HBV-DNA <2000 copies/mL and continue treatment during the study period.
- •For subjects infected with HCV:
- •If the infection is confirmed based on the detectable HCV ribonucleic acid RNA, such subjects cannot be included in the group.
- •If you are a fertile woman (that is, physically capable of getting pregnant), you must agree to take effective contraceptive measures during the study period and within 120 days after the last administration, and have urine within 7 days before the first study drug administration Or the serum pregnancy test is negative.
- •If you are a non-sterilized male, you need to agree to take effective contraceptive measures during the study period and 120 days after the last dose.
- •Life expectancy ≥ 3 months
排除标准
- •Diagnosed as mixed type of periampullary carcinoma, hepatocellular carcinoma and cholangiocarcinoma
- •Have received systemic treatment for biliary tumors in the past
- •Have previously received gemcitabine-based chemotherapy or TKI therapy or any tumor immunotherapy (for example, PD-1/L1 inhibitors, CTLA-4 inhibitors, etc.)
- •Have a history of severe hypersensitivity to other monoclonal antibodies
- •Allergy to tislelizumab or any of its excipients; allergy to oxaliplatin and any of its excipients; allergy to gemcitabine and any of its excipients; allergy to lenvatinib and any of its excipients
- •The presence of pericardial effusion, uncontrollable pleural effusion or clinically obvious ascites within 7 days before treatment is defined as meeting the following criteria: (a) Ascites can be detected by physical examination during screening, or (b) during screening, Ascites requires puncture fluid.
- •There is no clinical evidence of portal hypertension with esophageal or gastric varices within 6 months before starting treatment.
- •Any bleeding or thrombotic disease or any anticoagulant (such as warfarin or similar drugs) that needs to monitor the international standardized ratio during treatment within 6 months before the start of treatment
- •Has suffered from any malignant tumors, except for the BTC studied in this clinical trial and locally recurring cancers that have been cured (such as resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical or breast cancer) Carcinoma in situ, occult carcinoma of the thyroid).
- •Any known central nervous system metastasis and/or leptomeningeal disease have been present before treatment.
- •A history of any active immunodeficiency or autoimmune disease and/or any immunodeficiency or autoimmune disease that may recur at the time of screening
- •Note: Subjects with the following diseases can be selected:
- •Type I diabetes Hypothyroidism (if only hormone replacement therapy can be used to control) Controlled celiac disease Skin diseases that do not require systemic treatment (eg vitiligo, psoriasis, hair loss) Any other disease that will not recur without external triggers
- •Any disease requiring systemic treatment with corticosteroids (dose higher than 10mg/day of prednisone or equivalent doses of similar drugs) or other immunosuppressive agents in the 14 days before treatment.
- •Remarks: Subjects who have currently or previously used any of the following steroid regimens can be selected:
- •In the absence of active autoimmune diseases, adrenaline replacement steroids are allowed (prednisone ≤10mg/day or equivalent dose of similar drugs) Local, ophthalmic, intra-articular, intranasal and inhaled corticosteroids with minimal systemic absorption Prophylactic short-term use (≤7 days) corticosteroids (for example, allergy to contrast agents) or for the treatment of non-autoimmune conditions (for example, delayed hypersensitivity reactions caused by contact allergens)
- •There is a history of interstitial lung disease or non-infectious pneumonia.
- •Any serious chronic infection or active infection (excluding viral hepatitis) that requires systemic antibacterial, antifungal or antiviral therapy (such as tuberculosis) before starting treatment.
- •The electrocardiogram during screening showed that the QT interval (QTc) corrected according to the heart rate (corrected according to the Fridericia method) exceeded 450 msec.
- •Note: If any patient finds that the QTc interval exceeds 450 msec during the first ECG examination, the ECG will be repeated to confirm the result.
- •Any of the following cardiovascular risk factors: Cardiogenic chest pain in the 28 days before treatment, defined as moderate pain that restricts daily activities (ADL) Symptomatic pulmonary embolism occurred within 28 days before treatment A history of acute myocardial infarction occurred within 6 months before treatment.
- •Any history of heart failure reaching New York Heart Association grade III or IV within 6 months of treatment Ventricular arrhythmia of grade ≥2 occurred within 6 months before treatment Cerebrovascular accident (CVA) or transient ischemic attack (TIA) occurred within 6 months before treatment.
- •Have received organ transplantation or hematopoietic stem cell transplantation (HSCT) or any major surgery within 28 days before treatment.
- •Known mental or substance abuse disorders that may interfere with test compliance.
- •Live vaccine has been vaccinated 28 days before treatment. Note: Seasonal influenza vaccines are generally inactivated influenza vaccines and are allowed to be used.
- •Known history of human immunodeficiency virus infection (HIV) or syphilis infection.
- •The history or evidence of any disease, treatment, or laboratory abnormality that may confuse the test results, interfere with the participation of the subject during the entire trial, or the main investigator believes that it does not meet the subject's best benefit.
- •Currently participating in and receiving treatment, or participating in or participating in other drug or device research within 4 weeks after the first administration of the research drug.
- •From the screening visit to 120 days after the last drug administration, pregnancy or breastfeeding, or expectation of pregnancy or childbirth within the planned duration of the trial.
- •The investigator judges that the compliance is not good, or there are other conditions that make the patients unsuitable to participate in this trial.
- •There are various medical contraindications that prevent the use of enhanced imaging (CT or MRI).
- •There are surgical contraindications, and the researchers believe that it is not suitable for surgical patients.
研究组 & 干预措施
PD-1 antibody +Lenvatinib+Gemox
Experimental
Tilelizumab 200mg, d1 Q3W Lenvatinib 8mg, po, qd, Gemox chemotherapy Gemcitabine 1000mg/m2, d1, 8, Q3W, + oxaliplatin 85mg/m2 d1, Q3W
干预措施: PD-1+Lenvatinib+GEMOX (Drug)
结局指标
主要结局
R0 resection rate
时间窗: 24 months
the ratio of the number of R0 resection cases to the total number of enrolled cases
次要结局
- OS(24 months)
- ORR(24 months)
- DCR(24 months)
- PFS(24 months)
- MPR(24 months)
- CPR(24 months)
- RFS(24 months)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
2 期
A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker AnalysesHepatocellular CarcinomaNCT05897138Fujian Cancer Hospital30
Unknown
2 期
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaResectable Hepatocellular CarcinomaNCT04834986Tianjin Medical University Cancer Institute and Hospital30
招募中
2 期
Tislelizumab Plus Lenvatinib in Stage III-IV RCCAdvanced Kidney CancerNCT05485883Tianjin Medical University Second Hospital20
招募中
2 期
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCCRecurrent Hepatocellular CarcinomaNCT04615143Sun Yat-sen University80
招募中
1 期
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCCHepatocellular CarcinomaNCT05842317Peking Union Medical College Hospital60